The central laboratories arm of Ireland-based global CRO Icon has launched a global cytometry services offering through its facilities in New York, Dublin, Bangalore and Singapore, according to PharmaTimes.

The new service consists of two strands tailored to the particular testing requirements and development phase of a client’s compound.

Clients can work with Icon during the early stages of product development to create compound-specific assays. The Icon Central Laboratories R&D team will collaborate on developing a unique flow cytometry methodology, customized standard operating procedures and other special requirements including reporting, the company said.

These customized flow cytometry panels can then be used throughout the compound development lifecycle.

Icon's second cytometry services offering gives clients the choice of a range of fully validated assays and “is often suited to the large-scale, high-volume requirements of later phase global trials,” the company said.
 
Flow cytometry “has become a preferred testing method for many of our clients, particularly those with autoimmune, oncology and immunodeficiency compounds that require more specialized testing,” said Tom O’Leary, president of Icon Central Laboratories.